Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites.

Antimicrobial Agents and Chemotherapy
J M KovarikL Millerioux

Abstract

The pharmacokinetics of terbinafine and its inactive metabolites SDZ 86-621 (the N-demethyl form), SDZ 280-027 (the carboxybutyl form), and SDZ 280-047 (N-demethyl- carboxybutyl form) in plasma were characterized for 10 healthy male subjects receiving 250 mg of terbinafine orally once a day for 4 weeks and in the subsequent 8-week washout phase. Terbinafine concentrations were also measured in sebum, hair, nail, and stratum corneum samples. Concentrations of the parent compound and metabolites were determined by validated high-performance liquid chromatography methods. Terbinafine was rapidly absorbed, with peak concentrations in plasma of 1.70 +/- 0.77 micrograms/ml occurring 1.2 +/- 0.3 h postdose. Concentrations subsequently exhibited a triphasic decline, with a terminal deposition half-life of 16.5 +/- 2.8 days. Terbinafine accumulated approximately twofold over the 4-week dosing phase. The predominant metabolite in plasma samples was SDZ 280-027; specifically, the ratios of metabolite area under the curve to terbinafine area under the curve following the last dose were 1.25, 1.38, and 1.08 for metabolites SDZ 86-621, SDZ 280-027, and SDZ 280-047. Measurable concentrations of terbinafine were achieved in sebum and hair samp...Continue Reading

References

Feb 1, 1992·The British Journal of Dermatology·J G van der SchroeffJ Wuite
Mar 1, 1989·Clinical and Experimental Dermatology·J C Jensen
Sep 1, 1987·Antimicrobial Agents and Chemotherapy·G PetranyiH Mieth
Jan 20, 1995·Journal of Chromatography. B, Biomedical Applications·J DenouëlH Humbert

❮ Previous
Next ❯

Citations

Jun 22, 2000·Biomedical Chromatography : BMC·M H Yeganeh, A J McLachlan
Jan 1, 2014·Heart, Lung & Circulation·Abdul Rauf SheikhJohn F Beltrame
Aug 16, 2000·International Journal of Dermatology·S Jain, V N Sehgal
Oct 13, 2005·The Pediatric Infectious Disease Journal·Susan M Abdel-RahmanGilles-Jacques Rivière
Jan 26, 2011·Antimicrobial Agents and Chemotherapy·Alex van BelkumWendy W J van de Sande
Jan 20, 2000·Antimicrobial Agents and Chemotherapy·J MeletiadisP E Verweij
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·Peter D Walzer, Alan Ashbaugh
Jun 19, 2002·Antimicrobial Agents and Chemotherapy·Mahboubeh Hosseini-Yeganeh, Andrew J McLachlan
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jason G Newland, Susan M Abdel-Rahman
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Jul 28, 2001·Clinical Pharmacokinetics·D Debruyne, A Coquerel
Jan 27, 2016·Expert Opinion on Pharmacotherapy·Aditya K Gupta, Maria Cernea
Sep 2, 2015·Expert Review of Clinical Pharmacology·Shari R Lipner, Richard K Scher
Sep 19, 2014·Drug and Chemical Toxicology·Danielle TolomeottiValter Augusto Della-Rosa
Oct 31, 2009·Expert Opinion on Pharmacotherapy·S Krishnan-Natesan
Dec 18, 2001·Journal of Pharmaceutical Sciences·M Hosseini-Yeganeh, A J McLachlan
Oct 13, 2015·Journal of Viral Hepatitis·M A A van de KlundertN A Kootstra
Jun 9, 2004·International Journal of Cancer. Journal International Du Cancer·Pei-Yin HoWen-Sen Lee
Jun 10, 2003·International Journal of Cancer. Journal International Du Cancer·Wen-Sen LeeYuan-Soon Ho
Apr 16, 2011·Journal of Veterinary Pharmacology and Therapeutics·M M WilliamsB KuKanich
Aug 30, 2005·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Kuo-Ching YangYuan-Soon Ho
Jul 22, 2015·Drug Metabolism and Pharmacokinetics·Takeshi AkiyoshiHisakazu Ohtani
Dec 20, 2012·Psychiatry Investigation·Young-Min Park
Oct 22, 2016·MedChemComm·Huy X NgoKeith D Green
Aug 5, 2000·Rapid Communications in Mass Spectrometry : RCM·T K MajumdarF L Tse
Dec 29, 2016·American Journal of Veterinary Research·Michael H CourtDeeAnn M Reeder
Mar 10, 2012·Journal of Feline Medicine and Surgery·Ang WangZhenling Zeng
Dec 9, 2016·Expert Opinion on Drug Safety·Ioannis KyriakidisAndreas H Groll
Jan 25, 2017·Antimicrobial Agents and Chemotherapy·Tassanee LerksuthiratTheerapong Krajaejun
Sep 22, 2005·Therapeutic Drug Monitoring·Ingrid CastbergTrond O Aamo
Dec 13, 2002·American Journal of Clinical Dermatology·Malcolm J M DarkesKaren L Goa
Oct 28, 2019·European Journal of Hospital Pharmacy. Science and Practice·Astrid BacleJean-Pierre Gangneux

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.